Accepting Risk in Clinical Research: Is the Gene Therapy Field Becoming Too Risk-averse?

Abstract excerpt

Risk is an inescapable aspect of clinical research and is increasingly pertinent to the gene therapy field as the imperative for clinical trial activity grows. In recent years, the widely reported occurrence of serious adverse events (SAEs) in gene therapy studies, including trials for ornithine transcarbamylase (OTC) deficiency, X-linked severe combined immunodeficiency (SCID-X1), and rheumatoid arthritis, has...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomedical Ethics and Regulation
• Share to Ethics in Clinical Research
• Share to Virus-based gene therapy research